Search
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigational[A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the
Lomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Synonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDESafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalIt works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. … Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood.
Cemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigational[L39804] Cemiplimab was also approved by the European Commission on June 28, 2019. … [L43867] The EMA then approved Libtayo (cemiplimab) for that indication later in the same year. [L43872]
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … Food and Drug Administration (FDA) on 18 March 2010.
Synonyms: N-Carbamylglutamate, N-Carbamyl-L-glutamateInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnNicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent. … Niacin exists in different forms including nicotinic acid, nicotinamide and other derivatives such as inositol nicotinate.
Thiosulfuric acid
go.drugbank.com/drugs/DB09499ApprovedInvestigationalThiosulfuric acid is available in its salt forms sodium thiosulfate and sodium thiosulfate pentahydrate. … [A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical.
Categories: Compounds used in a research, industrial, or household settingBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigationalIt is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils. … [A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019]
Products: Fasenra Pen, Fasenra 30mg Solution for Injection in Pre-filled Pen